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Background: Chronic obstructive pulmonary disease (COPD) has been classically divided into blue bloaters
and pink puffers. The utility of these clinical subtypes is unclear. However, the broader distinction between
airway-predominant and emphysema-predominant COPD may be clinically relevant. The objective was to
define clinical features of emphysema-predominant and non-emphysematous COPD patients.
Methods: Current and former smokers from the Genetic Epidemiology of COPD Study (COPDGene) had chest
computed tomography (CT) scans with quantitative image analysis. Emphysema-predominant COPD was defined by
low attenuation area at −950 Hounsfield Units (LAA−950) ≥10%. Non-emphysematous COPD was defined by airflow
obstruction with minimal to no emphysema (LAA−950 < 5%).
Results: Out of 4197 COPD subjects, 1687 were classified as emphysema-predominant and 1817 as
non-emphysematous; 693 had LAA−950 between 5–10% and were not categorized. Subjects with
emphysema-predominant COPD were older (65.6 vs 60.6 years, p < 0.0001) with more severe COPD based on
airflow obstruction (FEV1 44.5 vs 68.4%, p < 0.0001), greater exercise limitation (6-minute walk distance 1138 vs
1331 ft, p < 0.0001) and reduced quality of life (St. George’s Respiratory Questionnaire score 43 vs 31, p < 0.0001).
Self-reported diabetes was more frequent in non-emphysematous COPD (OR 2.13, p < 0.001), which was also
confirmed using a strict definition of diabetes based on medication use. The association between diabetes and
non-emphysematous COPD was replicated in the ECLIPSE study.
Conclusions: Non-emphysematous COPD, defined by airflow obstruction with a paucity of emphysema on
chest CT scan, is associated with an increased risk of diabetes. COPD patients without emphysema may warrant
closer monitoring for diabetes, hypertension, and hyperlipidemia and vice versa.
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Chronic obstructive pulmonary disease (COPD) is a het-
erogeneous disease, including emphysema and large and
small airway disease. The most recent update from the
Global Initiative for Obstructive Lung Disease (GOLD)
has addressed COPD subgroups [1], and there is a rec-
ognized need to better define COPD subtypes [2]. Sev-
eral COPD subtypes have been shown to respond to
specific treatments, including long-term oxygen for hyp-
oxemic patients [3,4], lung volume reduction surgery for
upper lobe predominant emphysema [5], and medica-
tions including inhaled corticosteroids, azithromycin and
roflumilast for frequent acute exacerbations [6-8].
Classic COPD subtypes include the “pink puffer”
(underweight, emphysema, and normal resting oxygen
saturation) and the “blue bloater” (overweight, chronic
bronchitis, and hypoxemia) [9]. Though not appearing
in the GOLD document and other management guide-
lines [1,10], these subtypes persist in textbooks [11,12].
The pink puffer – blue bloater distinction is vaguely
defined and only applies to severe COPD patients,
potentially limiting its clinical utility. However, the dis-
tinction between airway-predominant and emphysema-
predominant COPD, which has some parallels to the
pink puffer – blue bloater classification, may still have
utility [13-17]. Historically, determinations about the
extent of emphysema and airway disease could only be
made on pathological specimens; however, chest com-
puted tomography (CT) scans provide extensive ana-
tomic information about COPD [18,19]. As chest CT
scans are becoming more frequently used for lung cancer
screening and other indications [20,21], these subtypes
may be more easily identified in COPD patients.
The Genetic Epidemiology of COPD Study (COPD-
Gene) has enrolled over 10,000 smokers with and without
COPD across the United States [22]. The large sample size
with extensive clinical data, including volumetric chest CT
scans, allows for COPD subtyping. We aimed to create
a simplified distinction between emphysema-predominant
and presumed airway-predominant COPD based on the
presence or absence of emphysema on chest CT scan. We
hypothesized that these COPD subtypes would show asso-
ciations with clinical characteristics and co-morbidities that
have implications for the evaluation and management of
patients with COPD. We assessed generalizability by repli-
cating subtype associations in the Evaluation of COPD
Longitudinally to Identify Predictive Surrogate End-points
(ECLIPSE) Study [23].
Methods
Study subjects
COPDGene enrolled smokers with and without COPD
at 21 clinical centers throughout the United States
between 2007–2011 [22]. Subjects were self-classifiednon-Hispanic whites and non-Hispanic African Americans
ages 45–80 with at least 10 pack-years of lifetime smoking.
During the study visit, subjects underwent a limited phys-
ical examination, spirometry before and after inhaled
bronchodilator, and a six-minute walk test to assess exer-
cise capacity. Subjects completed questionnaires on re-
spiratory disease, medical history and medications. The
St. George’s Respiratory Questionnaire (SGRQ) mea-
sured disease-related quality of life [24]. Study protocols
and questionnaires are available at www.copdgene.org. The
ECLIPSE study is described in the Supplementary Methods
(Additional file 1) [23]. COPDGene and ECLIPSE were
approved by the institutional review boards at Partners
Healthcare and all participating centers (Additional files 2
and 3). Subjects provided written informed consent.
Chest CT scans
All subjects underwent a volumetric chest CT scan per-
formed at full inspiration and at relaxed expiration. All
chest CT scans were subjected to a standard quality
control procedure. Quantitative image analysis was per-
formed using 3D SLICER [25,26] and VIDA Pulmonary
Workstation software (Vida Diagnostics, Coralville, Iowa).
Emphysema was quantified by the percent of lung voxels
with attenuation ≤ −950 Hounsfield Units (HU) on in-
spiratory scan [27]. Subjects were considered to have
emphysema-predominant COPD if this value exceeded
10%, corresponding to 3 standard deviations above the
mean in normal non-smokers from COPDGene [28]. In
contrast, non-emphysematous COPD was defined by min-
imal to absent emphysema, specifically <5% (mean +1 SD
in normal non-smokers). Airway disease was assessed by
the wall area percent of segmental airways and as the
square root wall area of a hypothetical airway with 10 mm
internal perimeter (SRWA-Pi10) [19].
Statistical analysis
We used the COPDGene dataset version date 19-
September-2012. The analysis was restricted to sub-
jects with airflow obstruction, defined by FEV1/FVC <0.7
after bronchodilator, corresponding to GOLD stages 1–4
[1]. Based on expert opinion and previous COPDGene
publications, we selected a set of clinical phenotypes and
comorbidities to compare across the imaging subtypes
(Table 1) [29-37]. Univariate comparisons used t-tests for
continuous variables and chi-squared tests for binary
variables. Logistic regression models were used to ad-
just for covariates including age, sex, race, body mass
index, current smoking status, lifetime pack-years of
smoking, and severity of airflow obstruction, assessed
as post-bronchodilator FEV1 percent predicted. Strati-
fied logistic regression models were adjusted for the
same covariates excluding the quantitative of categorical
variable that was used to define the strata (e.g. models in
Table 1 COPD characteristics and comorbidity definitions
Characteristic or comorbidity Definition COPDGene reference,
if applicable
Asthma-COPD overlap Self-report of physician diagnosis of asthma before age 40 Hardin 2011 [29]
Hypoxemia Resting oxygen saturation ≤88% Kim 2011 [30]
Frequent exacerbator 2 or more exacerbations requiring antibiotics and/or systemic steroids in
the year prior to enrollment
Han 2011 [33]
Severe, early-onset COPD Age < 55 years, FEV1 < 50% predicted Foreman 2011 [34]
Poor exercise capacity 6-minute walk distance <500 feet Rambod 2012 [32]
Bronchodilator response Increase in FEV1 200 ml and 12% from baseline
Pink puffer Emphysema > 10%, BMI≤ 20, O2 sat≥ 90%
Blue bloater Chronic bronchitis, BMI > 25, O2 sat < 90%
Chronic bronchitis Chronic cough and phlegm for ≥3 mo/yr for at least 2 consecutive years Kim 2011 [31]
Chronic prednisone use Self-report Swift 2012 [35]
Cardiovascular disease Self-report of heart attack, coronary artery disease, angina, angioplasty,
coronary artery bypass graft, congestive heart failure, peripheral vascular
disease, transient ischemic attack or stroke
Black-Shinn 2014 [36]
Coronary disease Self-report of heart attack, coronary artery disease, angina, angioplasty,
or coronary artery bypass graft
Congestive heart failure Self-report
Peripheral vascular disease Self-report
Cerebrovascular disease Self-report of transient ischemic attack or stroke
Sleep apnea Self-report
Diabetes mellitus Self-report Kinney 2014 [37]
Metabolic syndrome 3 of 4: BMI > 30 (measured), diabetes mellitus, hypertension, and high
cholesterol (all self-report)
Gastroesophageal reflux disease Self-report
Peptic ulcer disease Self-report
Osteoporosis Self-report
Figure 1 Frequencies of the “pink puffer” and “blue bloater”
subtypes of COPD by severity of airflow obstruction. See
Methods for definitions.
Hersh et al. BMC Pulmonary Medicine 2014, 14:164 Page 3 of 11
http://www.biomedcentral.com/1471-2466/14/164obese and non-obese subjects were not adjusted for BMI).
Analyses were performed using R statistical software.
Logistic regression analysis for diabetes in ECLIPSE is
described in the Additional file 1.
Results
COPDGene enrolled 10,300 subjects. There were 4197
current and former smokers with airflow obstruction
(FEV1/FVC < 0.7 on post-bronchodilator spirometry) and
inspiratory chest CT scans passing quality control included
in this analysis. Figure 1 demonstrates that the classic
COPD subtypes of pink puffers and blue bloaters increased
in frequency in more severe COPD, yet these subjects
remained infrequent even among subjects with the most
severe airflow obstruction (see Table 1 for definitions). Blue
bloaters were less common than pink puffers across all
level of lung function impairment.
Of the 4197 COPD subjects, 1687 subjects were
defined as emphysema-predominant and 1817 as non-
emphysematous (Table 2, Figure 2). 693 subjects had
Table 2 Demographic and clinical attributes of subjects with non-emphysematous and emphysema-predominant COPD
(GOLD 1–4)
No/minimal emphysema Emphysema-predominant p-value
N 1817 1687
Age 60.6 (±8.8) 65.6 (±7.7) <0.0001
Male sex 933 (51.3%) 1000 (59.3%) <0.0001
African American race 479 (26.4%) 288 (17.1%) <0.0001
Pack-years of smoking 47.3 (±24.4) 55.9 (±28.1) <0.0001
Current smoking 1122 (61.8%) 392 (23.2%) <0.0001
Body Mass Index, kg/m2 29.3 (±6.3) 25.9 (±5.2) <0.0001
Forced Expiratory Volume in 1 s (FEV1), % predicted 68.4 (±18.4) 44.5 (±21.0) <0.0001
GOLD Stage
1 487 (26.8%) 121 (7.2%)
2 1025 (56.4%) 453 (26.9%)
3 267 (14.7%) 649 (38.5%)
4 38 (2.1%) 464 (27.5%)
FEV1 / Forced Vital Capacity ratio 0.61 (±0.08) 0.42 (±0.12) <0.0001
Bronchodilator response, change in FEV1, % of baseline 7.2 (±11.7) 9.1 (±12.6) <0.0001
Bronchodilator response, change in FEV1, L 0.11 (±0.19) 0.09 (±0.13) 0.001
Bronchodilator response, % of predicted FEV1 3.8 (±6.4) 3.2 (±4.5) 0.002
6-minute walk distance, ft. 1331 (±383) 1138 (±403) <0.0001
Oxygen saturation by pulse oximetry, % 95.9 (±2.8) 94.0 (±3.9) <0.0001
Modified Medical Research Council dyspnea score 1.5 (±1.5) 2.4 (±1.3) <0.0001
St. George’s Respiratory Questionnaire total score 30.7 (±22.9) 43.0 (±20.6) <0.0001
BODE index* 1.6 (±1.7) 3.6 (±2.1) <0.0001
Emphysema at −950 Hounsfield units, % 2.0 (±1.4) 23.6 (±10.7) <0.0001
Square root wall area of an airway with 10 mm internal perimeter 3.71 (±0.15) 3.70 (±0.13) 0.001
Wall area % of segmental airways 62.7 (±3.4) 62.2 (±3.0) <0.0001
*BODE = Body mass, airflow Obstruction, Dyspnea, Exercise capacity [38].
Mean (±SD) or N (%) are shown.
Figure 2 Chest CT scans from COPDGene subjects demonstrating emphysema-predominant and non-emphysematous COPD.
(A) Emphysema-predominant: FEV1 55.8% predicted, 29.0% emphysema. (B) Non-emphysematous: FEV1 55.3% predicted, 4.2% emphysema.
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classified into one of the two categories (Additional file 4:
Table S1). Emphysema-predominant subjects had more
severe COPD, based on lower lung function, reduced
exercise capacity on 6-minute walk test, more severe
dyspnea, and reduced quality of life (higher scores on
SGRQ). Non-emphysematous subjects had greater bron-
chodilator responsiveness expressed as the absolute
change in FEV1 and as the change in FEV1 as a percent
of predicted FEV1, while emphysema-predominant sub-
jects had greater change expressed as a percent of base-
line FEV1. Non-emphysematous subjects had thicker
airways. The characteristics of the unclassified subjects
with 5–10% emphysema generally fell between the non-
emphysematous and emphysema predominant subjects
(Additional file 4: Table S1).
Table 3 shows the associations of the clinical charac-
teristics and co-morbidities with the imaging subtypes.
The COPD-asthma overlap group is more common
in non-emphysematous COPD, as is bronchodilator
responsiveness, when assessed using the American
Thoracic Society/European Respiratory Society criteria
[39]. Underweight subjects are more common amongTable 3 Associations of non-emphysematous and emphysema
and comorbidities
Non-emphysematou
COPD/asthma overlap 281 (15.5%)
Hypoxemia 44 (2.4%)
Frequent exacerbator 208 (11.4%)
Severe, early-onset COPD 91 (5.0%)
Poor exercise capacity 51 (2.8%)
Bronchodilator response, ATS/ERS definition [39] 634 (34.9%)
Chronic prednisone use 44 (2.4%)
Low body mass index 59 (3.2%)
Chronic bronchitis 470 (25.9%)
Cardiovascular disease 393 (21.6%)
Coronary disease 277 (15.2%)
Congestive heart failure 91 (5.0%)
Peripheral vascular disease 58 (3.2%)
Cerebrovascular disease 96 (5.3%)
Sleep apnea 271 (14.9%)
Diabetes mellitus 263 (14.5%)
Metabolic syndrome 360 (19.8%)
Gastroesophageal reflux disease 498 (27.4%)
Stomach ulcers 147 (8.1%)
Osteoporosis 278 (15.3%)
*All models were adjusted for age, sex, race, pack-years, current smoking status, BM
adjusted for the same covariates excluding BMI. Odds ratio is for non-emphysematoemphysema-predominant COPD. There was no differ-
ence in the prevalence of chronic bronchitis between the
two imaging subtypes. Cardiovascular disease by various
definitions, though statistically different between the im-
aging subtypes in the multivariate regression models, was
not seen more frequently in non-emphysematous sub-
jects, with the possible exception of congestive heart
failure (Table 3). Both diabetes mellitus and the meta-
bolic syndrome are significantly more common in non-
emphysematous COPD (diabetes OR 2.13, p < 0.0001;
metabolic syndrome OR 1.87, p < 0.0001). Using a stricter
diabetes definition of self-report plus medication use (see
methods in Additional file 1), there was a significant
association with non-emphysematous COPD (OR 2.45,
p < 0.0001). The associations with self-reported dia-
betes and the metabolic syndrome were similar in ana-
lyses restricted to subjects with FEV1 < 80% predicted
(data not shown).
To ensure that the associations with diabetes and the
metabolic syndrome were not due to confounding, we
performed logistic regression analyses stratified by vari-
ous potential confounding factors (Table 4 and Additional
file 4: Table S2). The increased frequency of diabetes in-predominant COPD with other clinical subgroups
Frequency Logistic regression
s Emphysema-predominant OR (adjusted)* p-value
178 (10.6%) 1.64 0.0006
159 (9.4%) 0.76 0.2
330 (19.6%) 0.88 0.3
111 (6.6%) 1.07 0.9
119 (7.1%) 0.93 0.8
569 (33.7%) 1.20 0.05
124 (7.4%) 0.73 0.2
180 (10.7%) 0.39 <0.0001
431 (25.5%) 0.87 0.2
399 (23.7%) 1.44 0.0009
278 (16.5%) 1.36 0.01
59 (3.5%) 3.76 <0.0001
53 (3.1%) 1.59 0.07
102 (6.0%) 1.14 0.5
199 (11.8%) 1.17 0.3
146 (8.7%) 2.13 <0.0001
173 (10.3%) 1.87 <0.0001
511 (30.3%) 0.93 0.5
183 (10.8%) 0.76 0.07
372 (22.1%) 0.96 0.7
I, and FEV1% predicted, except low body mass index regression which was
us compared to emphysema-predominant COPD.
Table 4 Stratified logistic regression analyses for diabetes
Variable Stratum Non-emphysematous Emphysema-predominant OR (adjusted)* p-value
Obesity BMI≤ 30 89 (8.2%) 90 (6.6%) 1.82 0.004
BMI > 30 174 (23.8%) 56 (17.0%) 2.71 <0.001
Current smoker No 126 (18.1%) 123 (9.5%) 1.87 <0.001
Yes 137 (12.2%) 23 (5.9%) 2.85 <0.001
GOLD Stage 1–2 191 (12.6%) 47 (8.2%) 1.87 0.001
3–4 72 (23.6%) 99 (8.9%) 2.11 0.001
Race Non-Hispanic white 185 (13.8%) 113 (8.1%) 2.23 <0.001
African American 78 (16.3%) 33 (11.5%) 1.96 0.02
Age <65 147 (11.8%) 53 (7.1%) 2.07 0.001
≥65 116 (20.2%) 93 (9.9%) 2.16 <0.001
*Models were adjusted for age, sex, race, pack-years, current smoking status, BMI, and FEV1% predicted, excluding the variable that was used to define the strata
(e.g. models in obese and non-obese subjects were not adjusted for BMI). Odds ratio is for non-emphysematous compared to emphysema-predominant COPD.
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of obese and non-obese subjects, current and former
smokers, mild-moderate (GOLD 1–2) and severe-very
severe COPD (GOLD 3–4), non-Hispanic white and
African American subjects, and older and younger sub-
jects (Table 4). Odds ratios were similar or increased in
the stratified analyses using the stricter diabetes defin-
ition of self-report plus medication (data not shown).
The associations with metabolic syndrome persisted in
stratified analyses (Table S2).
In ECLIPSE, there were 283 non-emphysema predom-
inant and 1211 emphysema-predominant COPD sub-
jects (Additional file 4: Table S3). Similar to COPDGene,
emphysema-predominant subjects had more severe air-
flow obstruction. Diabetes was reported by 10.6% of non-
emphysematous and 8.2% of emphysema-predominant
subjects. A logistic regression model replicated the associ-
ation between diabetes and non-emphysema predominant
COPD (OR 1.62, 1-sided p-value = 0.034).
Discussion
In the COPDGene Study, we defined subtypes of
emphysema-predominant and non-emphysematous COPD
based on a distinction between high and low emphysema
on chest CT scan. We found an increased prevalence of
diabetes in non-emphysematous COPD subjects, which
was confirmed in the ECLIPSE study. Subjects with
emphysema-predominant COPD had more severe air-
flow obstruction, but the proportions of subjects with
frequent exacerbations or exercise intolerance were similar
in the two subgroups when adjusted for differences in lung
function. We confirmed expected associations of asthma-
COPD overlap syndrome with non-emphysematous COPD
and low BMI with emphysema-predominant COPD. The
classic pink puffer – blue bloater subtypes were found in
low frequencies in a modern COPD population. There was
no difference in the rate of chronic bronchitis across thetwo subtypes, highlighting another shortcoming of this
classic dichotomy. The pink puffer – blue bloater distinc-
tion is unlikely to be useful and should be abandoned.
The heterogeneous nature of COPD is increasingly
recognized [2]. Previous efforts to identify subtypes of
COPD have relied on statistical approaches such as clus-
ter analysis and have identified clusters with emphysema
and airway-predominant disease [40-42]. Garcia-Aymerich
and colleagues found a cluster of subjects with milder
COPD, obesity, diabetes, and cardiovascular disease, who
had less emphysema in those subjects with CT scans [43].
These statistical approaches are promising, but they often
require a large number of input variables and the output
may be difficult to interpret. In our analysis, the simple dis-
tinction based on the presence or absence of emphysema
yielded similar results and may be easier to apply clinically
than the cluster-based methods.
Diabetes and the metabolic syndrome are frequent co-
morbidities in COPD patients [44-47]. COPD, diabetes,
and the metabolic syndrome are all related to systemic
inflammation, which may explain the co-occurrence.
Studies examining whether inhaled corticosteroids in-
crease risk of diabetes have shown conflicting results
[48,49]. Regardless, any association between ICS and
diabetes would not explain the high frequency of the
other components of the metabolic syndrome in COPD.
In a subset of COPDGene subjects, Han and col-
leagues examined CT features associated with COPD
exacerbations [33]. They found that diabetes was more
frequent in subjects with airway disease, defined by air-
way wall measures. The current study using all COPD
subjects in COPDGene extends those results, using a
paucity of emphysema on CT scan as a surrogate for
airway-predominant COPD. The concordant results
using a simple definition of airway-predominant COPD
strengthens the current findings. Inflammation in emphy-
sema may be different from inflammation in airway disease
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COPD phenotypes and other diseases associated with sys-
temic inflammation. Analyses within well-characterized
cohorts of COPD patients including biomarkers, chest CT
scans and comorbidities would be required to clarify these
inflammatory phenotypes.
The observation that non-emphysematous COPD is
associated with diabetes may have clinical implications.
Current guidelines from the U.S. Preventive Services
Task Force (USPTF) and other organizations recom-
mend routine screening for hypertension and hyperlipid-
emia in adults [51]. However, recommendations for
diabetes screening vary. The USPTF recommends dia-
betes screening only in adults with blood pressure
greater than 135/80 mmHg [52]. The American Diabetes
Association recommends screening all adults who are
overweight and have one or more risk factors for dia-
betes, as well as all adults beginning at age 45 [53].
One might consider adding COPD, specifically non-
emphysematous COPD, to the list of diabetes risk factors.
With the increasing use of chest CT scans for screening
and diagnosis, physicians will increasingly be able to
identify COPD patients with and without emphysema.
Since patients with chronic diseases may be under-
treated for other medical conditions [54], our results
serve as a reminder to physicians to screen for diabetes,
hypertension, and lipid disorders in patients with non-
emphysematous COPD. Conversely, clinicians should
obtain spirometry in current and former smokers with
diabetes and/or metabolic syndrome who present with
respiratory symptoms.
Besides a heightened awareness of disease screening in
patients with non-emphysematous COPD, our find-
ings may potentially affect treatment. For example,
the phosphodiesterase-4 inhibitor roflumilast is indicated
in severe COPD patients with chronic bronchitis and fre-
quent acute exacerbations [8]. Wouters et al. have shown
that roflumilast improves glucose control in subjects with
newly-diagnosed diabetes without COPD [55]. The effect
of roflumilast on both COPD and diabetes outcomes in
subjects with both diseases warrants further study. Since
we found that chronic bronchitis was equally frequent in
both imaging subtypes, non-emphysematous COPD may
define a more specific subgroup that might benefit from
roflumilast than does chronic bronchitis. Other anti-
inflammatory agents may also have beneficial effects in
COPD subtypes. Our analysis has several limitations.
We divided subjects into emphysema-predominant and
non-emphysematous COPD, as a surrogate for airway-
predominant COPD [17]. The non-emphysematous sub-
group did have large airway disease on chest CT scans.
However, the major site of airflow limitation is in the small
airways. Measurements of small airways (<2 mm) are lim-
ited due to the spatial resolution of CT scans. Additionally,the emphysema-predominant subtype may still include
substantial airway disease since we did not account for
CT airway measurements when defining the subtypes.
In order to be clinically-relevant, we created a simple
distinction on chest CT scans which does not require
complex airway measurements. The quantitative CT
emphysema categories served as a surrogate for visual
reading of the presence or absence of emphysema, as
would be found in a clinical radiology report. Stan-
dardized radiologist readings of chest CT scans were
not available in COPDGene. However, this simplified
distinction proved to be generalizable to a second study
population which included COPD subjects from multiple
countries.
In COPDGene, comorbidities were defined by subject
self-report. Previous studies have shown subject report
of diabetes to be reliable [56-58]. In addition, we con-
firmed our findings using a strict definition of diabetes
including medication usage. However, we could not
apply strict definitions of metabolic syndrome, which
would require measurements of waist circumference
and triglyceride, HDL, and glucose levels [59]. Using
more precise definitions may strengthen the associa-
tions found using self-reported data. Additionally, we
used cross-sectional data, so we cannot determine the
relative timing of the onset of non-emphysematous
COPD and diabetes and the metabolic syndrome. Lon-
gitudinal data would be needed to address causality.
COPDGene and ECLIPSE included non-Hispanic white
and non-Hispanic African American subjects; it is not
known whether our findings are generalizable to other
racial and ethnic groups.
Conclusions
Despite these limitations, we were able to create an
imaging-based classification of emphysema-predominant
and non-emphysematous COPD. The emphysema-
predominant subjects had more severe COPD, based on
measures of lung function, exercise capacity and symp-
toms. However, the non-emphysematous COPD subjects
had an increased prevalence of diabetes and the meta-
bolic syndrome, consistent with systemic inflammation.
This finding may encourage clinicians to screen for
diabetes and lipid abnormalities in COPD patients, speci-
fically those without significant emphysema. With the
increase in chest CT scans being performed for other in-
dications, such as lung cancer screening, COPD patients
will be more easily able to be assigned to these imaging
subtypes. Conversely, patients with diabetes or metabolic
syndrome who present with respiratory symptoms should
undergo spirometry to evaluate for COPD. Future studies
of existing and novel anti-inflammatory agents in COPD
may find better results if targeted to COPD subjects
without substantial emphysema.
Hersh et al. BMC Pulmonary Medicine 2014, 14:164 Page 8 of 11
http://www.biomedcentral.com/1471-2466/14/164Additional files
Additional file 1: Supplementary Methods.
Additional file 2: COPDGene Institutional Review Board approvals.
Additional file 3: ECLIPSE Institutional Review Board approvals.
Additional file 4: Table S1. Demographic and clinical attributes of
subjects with non-emphysematous and emphysema-predominant COPD
(GOLD 1–4), along with unclassified COPD subjects (5–10% emphysema).
Table S2. Stratified logistic regression analyses in COPDGene for metabolic
syndrome. Table S3. ECLIPSE subjects with non-emphysematous and
emphysema-predominant COPD (GOLD 2–4).
Abbreviations
BODE: Body mass index, airflow obstruction, dyspnea, and exercise capacity;
COPD: Chronic obstructive pulmonary disease; COPDGene: Genetic
epidemiology of COPD study; ECLIPSE: Evaluation of COPD longitudinally to
identify predictive surrogate end-points; FEV1: Forced expiratory volume in
1 second; FVC: Forced vital capacity; GOLD: Global initiative for chronic
obstructive lung disease; OR: Odds ratio; SGRQ: St. George’s respiratory
questionnaire.
Competing interests
Dr. Hersh has received lecture fees from Novartis and has been a consultant
for CSL Behring. Dr. Make reports advisory board membership for Forest,
AstraZeneca, Novartis, Covidien, Breathe, Merck, Sunovion, Boehringer
Ingelheim, MedImmune, Ikaria, and Abbot. He has been a consultant for
Astellas, Forest, and Boehringer Ingelheim. He has received research grants
from AstraZeneca, GlaxoSmithKline, NABI, Boehringer Ingelheim, Sunovion,
Forest, and Pfizer. He has received lecture fees from GlaxoSmithKline,
Boehringer Ingelheim, Forest, and Pfizer. Dr. Lynch has been a consultant
for Perceptive Imaging, Boehringer Ingelheim, Genentech, Gilead, and
Intermune. He has received grants from Centocor and Siemens. Dr. Barr has
received royalties from UpToDate. Dr. Cho has been a consultant for Merck.
Dr. Han has been a consultant for GlaxoSmithKline, Boehringer Ingelheim,
Novartis, Genentech, Medimmune, and Forest. She has received lecture fees
from GlaxoSmithKline, Boehringer Ingelheim,, Pfizer, Novartis, Grifols, and
Forest. She has received royalties from UpToDate. Dr. Ramsdell has received
a research grant from Boehringer Ingelheim. Dr. Rennard has received grants
from AstraZeneca, Biomarck, Centocor, Mpex, Nabi, Novartis, Otsuka,
Boehringer Ingelheim, and Nycomed. He has been a consultant for Able
Associates, Adelphi Research, APT Pharma/Britnall, Aradigm, AstraZeneca,
Boehringer Ingelheim, Chiesi, CommonHealth, Consult Complete,
COPDForum, Data Monitor, Decision Resource, Defined Health, Dey, Dunn
Group, Easton Associates, Equinox, Gerson, GlaxoSmithKline, Infomed, KOL
Connection, M. Pankove, MedaCorp, MDRX Financial, Mpex, Novartis, Oriel
Therapeutics, Otsuka, Pennside, ParmaVentures, Pharmaxis, Price Waterhouse,
Propagate, Pulmatrix, Reckner Associates, recruiting Resources, Roche,
Schlesinger Medical, Scimed, Sudler and Hennessey, TargeGen, Theravance,
UBC, Uptake Medical, VantagePoint Management, Forest, Nycomed, Pearl
and Sanyko. He has served on advisory boards for Almirall, Novartis,
Nycomed, and Pfizer. He has received lecture fees from AAAAI, American
College of Osteopathic Physicians, Asan Medical Center, American Thoracic
Society, AstraZeneca, California Society of Allergy, Convergent Health
Solutions for Reviews and Trends in COPD, COPD Foundation, Creative
Educational Concepts, Dey, Duke University, France Foundation, Information
TV, University of Southern California, Network for Continuing Education
(CHARM), Novartis, Nycomed, Otsuka, Pfizer, Sarasota Memorial Hospital,
Spanish Thoracic Society, University of Washington, University of Alabama
Birmingham, University of Pittsburgh, University of British Columbia,
University of California Davis, and Sioux Falls VA. Dr. Sciurba has participated
in consulting for GSK, AstraZeneca and Pfizer and has received research
grant funding from the NIH, GSK, BI, Pfizer, Forest and Actelion. Dr. Steiner
reports royalties from Elsevier Publishing and consultancy for Johnson and
Johnson. Dr. van Beek is a board member of Quantitative Clinical Trials
Imaging Services, Inc. He has been a consultant for Siemens Medical
Systems, Synta Pharmaceuticals, and Skolkovo Foundation. He has received
speaking fees from Vital Images Inc and Toshiba Medical Systems. Dr. Silverman
has been a consultant for GlaxoSmithKline, AstraZeneca, and Merck. He has
received research grants from GlaxoSmithKline. He has received speaking feesfrom GlaxoSmithKline and AstraZeneca. Dr. Calverley reports advisory
board membership for AstraZeneca, Merck, Boehringer Ingelheim, GSK
and Takeda. He has been a consultant for Boehringer Ingelheim, GSK and
Takeda. He has received research grants from GlaxoSmithKline, Boehringer
Ingelheim, and Takeda. Dr. Coxson has received consulting fees and
research grants from GlaxoSmithKline and a research grant from Spiration.
Dr. Tal-Singer is an employee and shareholder of GlaxoSmithKline. Drs.
Bowler, Castaldi, DeMeo, Foreman, Hokanson, Lutz, Regan, Schroeder and
Crapo and Mr. Harshfield report no disclosures.Authors’ contributions
Concept and design: CPH, BJM, EKS and JDC. Acquisition of data: CPH, BJM,
DAL, RGB, RPB, HOC, PMAC, DLDM, MGF, MKH, JWR, EAR, SIR, JDS, FCS, RMS,
EKS and JDC. Analysis and interpretation of data: CPH, BJM, DAL, PJC, MHC,
HOC, BJH, JEH, SL, SIR, EJRB, JDS, EKS and JDC. Drafting of manuscript: CPH.
Critical revision of manuscript: CPH, BJM, DAL, RGB, RPB, PMAC, PJC, MHC,
HOC, DLDM, MGF, MKH, BJH, JEH, SL, JWR, EAR, SIR, JDS, FCS, RMS, RTS, EJRB,
EKS, JDC. Funding: CPH, EKS, JDC. All authors read and approved the final
manuscript.Funding
Supported by U.S. National Institutes of Health grants R01HL094635 (CPH),
R01NR013377 (CPH), R01HL089856 (EKS), R01HL089897 (JDC), P01HL105339
(EKS). COPDGene is also supported by the COPD Foundation through
contributions made to an Industry Advisory Board comprised of
AstraZeneca, Pfizer, Novartis, Boehringer-Ingelheim, Siemens, Sunovion,
and GlaxoSmithKline. ECLIPSE is supported by GlaxoSmithKline. The
sponsors had no role in study design; collection, analysis, and interpretation
of the data; preparation of the manuscript; and decision to submit the
manuscript for publication.
COPDGene® Investigators - Core Units
Administrative Core: James Crapo, MD (PI), Edwin Silverman, MD, PhD (PI),
Barry Make, MD, Elizabeth Regan, MD, Rochelle Lantz, Lori Stepp, Sandra
Melanson
Genetic Analysis Core: Terri Beaty, PhD, Nan Laird, PhD, Christoph Lange, PhD,
Michael Cho, MD, Stephanie Santorico, PhD, John Hokanson, MPH, PhD,
Dawn DeMeo, MD, MPH, Nadia Hansel, MD, MPH, Craig Hersh, MD, MPH,
Peter Castaldi, MD, MSc, Merry-Lynn McDonald, PhD, Jin Zhou, PhD, Manuel
Mattheisen, MD, Emily Wan, MD, Megan Hardin, MD, Jacqueline Hetmanski,
MS, Margaret Parker, MS, Tanda Murray, MS
Imaging Core: David Lynch, MB, Joyce Schroeder, MD, John Newell, Jr., MD,
John Reilly, MD, Harvey Coxson, PhD, Philip Judy, PhD, Eric Hoffman, PhD,
George Washko, MD, Raul San Jose Estepar, PhD, James Ross, MSc, Mustafa
Al Qaisi, MD, Jordan Zach, Alex Kluiber, Jered Sieren, Tanya Mann, Deanna
Richert, Alexander McKenzie, Jaleh Akhavan, Douglas Stinson
PFT QA Core, National Jewish Health: Robert Jensen, PhD
Biological Repository, Johns Hopkins University, Baltimore, MD: Homayoon
Farzadegan, PhD, Stacey Meyerer, Shivam Chandan, Samantha Bragan
Data Coordinating Center and Biostatistics, National Jewish Health, Denver, CO:
Douglas Everett, PhD, Andre Williams, PhD, Carla Wilson, MS, Anna Forssen,
MS, Amber Powell, Joe Piccoli
Epidemiology Core, University of Colorado School of Public Health, Denver, CO:
John Hokanson, MPH, PhD, Marci Sontag, PhD, Jennifer Black-Shinn, MPH,
Gregory Kinney, MPH, PhDc, Sharon Lutz, MPH, PhD
COPDGene® Investigators: Clinical Centers
Ann Arbor VA: Jeffrey Curtis, MD, Ella Kazerooni, MD
Baylor College of Medicine, Houston, TX: Nicola Hanania, MD, MS, Philip Alapat, MD,
Venkata Bandi, MD, Kalpalatha Guntupalli, MD, Elizabeth Guy, MD, Antara
Mallampalli, MD, Charles Trinh, MD, Mustafa Atik, MD, Hasan Al-Azzawi, MD,
Marc Willis, DO, Susan Pinero, MD, Linda Fahr, MD, Arun Nachiappan, MD,
Collin Bray, MD, L. Alexander Frigini, MD, Carlos Farinas, MD, David Katz, MD,
Jose Freytes, MD, Anne Marie Marciel, MD
Brigham and Women’s Hospital, Boston, MA: Dawn DeMeo, MD, MPH, Craig
Hersh, MD, MPH, George Washko, MD, Francine Jacobson, MD, MPH, Hiroto
Hatabu, MD, PhD, Peter Clarke, MD, Ritu Gill, MD, Andetta Hunsaker, MD,
Beatrice Trotman-Dickenson, MBBS, Rachna Madan, MD
Columbia University, New York, NY: R. Graham Barr, MD, DrPH, Byron Thomashow,
MD, John Austin, MD, Belinda D’Souza, MD
Duke University Medical Center, Durham, NC: Neil MacIntyre, Jr., MD, Lacey
Washington, MD, H Page McAdams, MD
Hersh et al. BMC Pulmonary Medicine 2014, 14:164 Page 9 of 11
http://www.biomedcentral.com/1471-2466/14/164Reliant Medical Group, Worcester, MA: Richard Rosiello, MD, Timothy
Bresnahan, MD, Joseph Bradley, MD, Sharon Kuong, MD, Steven Meller, MD,
Suzanne Roland, MD
Health Partners Research Foundation, Minneapolis, MN: Charlene McEvoy, MD,
MPH, Joseph Tashjian, MD
Johns Hopkins University, Baltimore, MD: Robert Wise, MD, Nadia Hansel, MD,
MPH, Robert Brown, MD, Gregory Diette, MD, Karen Horton, MD
Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance,
CA: Richard Casaburi, MD, PhD, Janos Porszasz, MD, PhD, Hans Fischer, MD,
Matt Budoff, MD
Michael E. DeBakey VAMC, Houston, TX: Amir Sharafkhaneh, MD, Charles Trinh,
MD, Hirani Kamal, MD, Roham Darvishi, MD, Marc Willis, DO, Susan Pinero,
MD, Linda Fahr, MD, Arun Nachiappan, MD, Collin Bray, MD, L. Alexander
Frigini, MD, Carlos Farinas, MD, David Katz, MD, Jose Freytes, MD, Anne Marie
Marciel, MD
Minneapolis VA: Dennis Niewoehner, MD, Quentin Anderson, MD,
Kathryn Rice, MD, Audrey Caine, MD
Morehouse School of Medicine, Atlanta, GA: Marilyn Foreman, MD, MS, Gloria
Westney, MD, MS, Eugene Berkowitz, MD, PhD
National Jewish Health, Denver, CO: Russell Bowler, MD, PhD, David Lynch,
MB, Joyce Schroeder, MD, Valerie Hale, MD, John Armstrong, II, MD, Debra
Dyer, MD, Jonathan Chung, MD, Christian Cox, MD
Temple University, Philadelphia, PA: Gerard Criner, MD, Victor Kim, MD,
Nathaniel Marchetti, DO, Aditi Satti, MD, A. James Mamary, MD, Robert
Steiner, MD, Chandra Dass, MD, Libby Cone, MD
University of Alabama, Birmingham, AL: William Bailey, MD, Mark Dransfield, MD,
Michael Wells, MD, Surya Bhatt, MD, Hrudaya Nath, MD, Satinder Singh, MD
University of California, San Diego, CA: Joe Ramsdell, MD, Paul Friedman, MD
University of Iowa, Iowa City, IA: Alejandro Cornellas, MD, John Newell, Jr., MD,
Edwin JR van Beek, MD, PhD
University of Michigan, Ann Arbor, MI: Fernando Martinez, MD, MeiLan Han,
MD, Ella Kazerooni, MD
University of Minnesota, Minneapolis, MN: Christine Wendt, MD, Tadashi Allen, MD
University of Pittsburgh, Pittsburgh, PA: Frank Sciurba, MD, Joel Weissfeld, MD,
MPH, Carl Fuhrman, MD, Jessica Bon, MD, Danielle Hooper, MD
University of Texas Health Science Center at San Antonio, San Antonio, TX:
Antonio Anzueto, MD, Sandra Adams, MD, Carlos Orozco, MD, Mario Ruiz, MD,
Amy Mumbower, MD, Ariel Kruger, MD, Carlos Restrepo, MD, Michael Lane, MD
Principal investigators and centers participating in ECLIPSE include: Bulgaria:
Y. Ivanov, Pleven; K. Kostov, Sofia. Canada: J. Bourbeau, Montreal QC; M.
Fitzgerald, Vancouver BC; P. Hernández, Halifax NS; K. Killian, Hamilton ON;
R. Levy, Vancouver BC; F. Maltais, Montreal QC; D. O'Donnell, Kingston ON.
Czech Republic: J. Krepelka, Prague. Denmark: J. Vestbo, Hvidovre. The
Netherlands: E. Wouters, Horn-Maastricht. New Zealand: D. Quinn, Wellington.
Norway: P. Bakke, Bergen. Slovenia: M. Kosnik, Golnik. Spain: A. Agusti, J. Sauleda,
Palma de Mallorca. Ukraine: Y. Feschenko, V. Gavrisyuk, L. Yashina, Kiev;
N. Monogarova, Donetsk. United Kingdom: P. Calverley, Liverpool; D. Lomas,
Cambridge; W. MacNee, Edinburgh; D. Singh, Manchester; J. Wedzicha,
London. United States: A. Anzueto, San Antonio, TX; S. Braman, Providence. RI;
R. Casaburi, Torrance CA; B. Celli, Boston, MA; G. Giessel, Richmond, VA;
M. Gotfried, Phoenix, AZ; G. Greenwald, Rancho Mirage, CA; N. Hanania,
Houston, TX; D. Mahler, Lebanon, NH; B. Make, Denver, CO; S. Rennard,
Omaha, NE; C. Rochester, New Haven, CT; P. Scanlon, Rochester, MN; D.
Schuller, Omaha, NE; F. Sciurba, Pittsburgh, PA; A. Sharafkhaneh, Houston, TX;
T. Siler, St Charles, MO; E. Silverman, Boston, MA; A. Wanner, Miami, FL; R. Wise,
Baltimore, MD; R. ZuWallack, Hartford, CT.
Steering Committee: H. Coxson (Canada), C. Crim (GlaxoSmithKline, USA),
L. Edwards (GlaxoSmithKline, USA), D. Lomas (UK), W. MacNee (UK), E. Silverman
(USA), R. Tal Singer (Co-chair, GlaxoSmithKline, USA), J. Vestbo (Co-chair,
Denmark), J. Yates (GlaxoSmithKline, USA).
Scientific Committee: A. Agusti (Spain), P. Calverley (UK), B. Celli (USA), C. Crim
(GlaxoSmithKline, USA), B. Miller (GlaxoSmithKline, USA), W. MacNee (Chair, UK),
S. Rennard (USA), R. Tal-Singer (GlaxoSmithKline, USA), E. Wouters
(The Netherlands), J. Yates (GlaxoSmithKline, USA).
Author details
1Channing Division of Network Medicine, Boston, MA, USA. 2Division of
Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital,
Boston, MA, USA. 3Division of Pulmonary and Critical Care Medicine, National
Jewish Health, Denver, CO, USA. 4Department of Radiology, National Jewish
Health, Denver, CO, USA. 5Department of Medicine, Columbia University,New York, NY, USA. 6Division of Infection and Immunity Clinical Sciences
Centre, University Hospital Aintree, Liverpool, UK. 7Department of Radiology,
University of British Columbia, Vancouver, Canada. 8Division of Pulmonary
and Critical Care Medicine, Morehouse School of Medicine, Atlanta, GA, USA.
9Division of Pulmonary and Critical Care Medicine, University of Michigan
Health System, Ann Arbor, MI, USA. 10Department of Epidemiology, Colorado
School of Public Health, Aurora, CO, USA. 11Department of Biostatistics,
Colorado School of Public Health, Aurora, CO, USA. 12Division of Pulmonary
and Critical Care Medicine, University of California, San Diego, CA, USA.
13Division of Pulmonary, Critical Care, Sleep and Allergy, University of
Nebraska Medical Center, Omaha, NE, USA. 14Division of Pulmonary, Allergy,
and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
15Department of Radiology, Temple University, Philadelphia, PA, USA.
16GlaxoSmithKline R&D, King of Prussia, PA, USA. 17Department of Radiology,
University of Edinburgh, Edinburgh, Scotland.
Received: 6 May 2014 Accepted: 9 October 2014
Published: 24 October 2014
References
1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A,
Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD,
Rodriguez-Roisin R: Global strategy for the diagnosis, management,
and prevention of chronic obstructive pulmonary disease: GOLD
executive summary. Am J Respir Crit Care Med 2012, 187(4):347–365.
2. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM,
Goldin JG, Jones PW, Macnee W, Make BJ, Rabe KF, Rennard SI, Sciurba FC,
Silverman EK, Vestbo J, Washko GR, Wouters EF, Martinez FJ: Chronic
obstructive pulmonary disease phenotypes: the future of COPD. Am J
Respir Crit Care Med 2010, 182(5):598–604.
3. Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen
therapy in hypoxemic chronic obstructive lung disease: a clinical trial.
Ann Intern Med 1980, 93(3):391–398.
4. Medical Research Council Working Party: Long term domiciliary oxygen
therapy in chronic hypoxic cor pulmonale complicating chronic
bronchitis and emphysema. Lancet 1981, 1(8222):681–686.
5. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A,
Weinmann G, Wood DE: A randomized trial comparing lung-volume-
reduction surgery with medical therapy for severe emphysema. N Engl J
Med 2003, 348(21):2059–2073.
6. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, Curtis JL,
Dransfield MT, Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ,
Madinger NE, McEvoy C, Niewoehner DE, Porsasz J, Price CS, Reilly J,
Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR,
COPD Clinical Research Network: Azithromycin for prevention of
exacerbations of COPD. N Engl J Med 2011, 365(8):689–698.
7. Yang IA, Fong KM, Sim EH, Black PN, Lasserson TJ: Inhaled corticosteroids
for stable chronic obstructive pulmonary disease. Cochrane Database Syst
Rev 2007, 2:CD002991.
8. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ:
Roflumilast in symptomatic chronic obstructive pulmonary disease: two
randomised clinical trials. Lancet 2009, 374(9691):685–694.
9. Dornhorst AC: Respiratory insufficiency. Lancet 1955, 268(6876):1185–1187.
10. Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T,
Marciniuk DD, Denberg T, Schunemann H, Wedzicha W, MacDonald R,
Shekelle P, American College of Physicians, American College of Chest
Physicians, American Thoracic Society, European Respiratory Society:
Diagnosis and management of stable chronic obstructive pulmonary
disease: a clinical practice guideline update from the American College
of Physicians, American College of Chest Physicians, American Thoracic
Society, and European Respiratory Society. Ann Intern Med 2011,
155(3):179–191.
11. Weinberger SE, Cockrill BA, Mandel J: Chronic obstructive pulmonary
disease. In Principles of Pulmonary Medicine. 5th edition. Philadelphia:
Saunders Elsevier; 2008:90–109.
12. Niewoehner DE: Chronic obstructive pulmonary disease. In Goldman’s
Cecil Medicine. 24th edition. Edited by Goldman L, Schafer AI. Philadelphia:
Elsevier Saunders; 2012:537–544.
13. Boschetto P, Miniati M, Miotto D, Braccioni F, De Rosa E, Bononi I, Papi A,
Saetta M, Fabbri LM, Mapp CE: Predominant emphysema phenotype in
chronic obstructive pulmonary. Eur Respir J 2003, 21(3):450–454.
Hersh et al. BMC Pulmonary Medicine 2014, 14:164 Page 10 of 11
http://www.biomedcentral.com/1471-2466/14/16414. Makita H, Nasuhara Y, Nagai K, Ito Y, Hasegawa M, Betsuyaku T, Onodera Y,
Hizawa N, Nishimura M: Characterisation of phenotypes based on severity
of emphysema in chronic obstructive pulmonary disease. Thorax 2007,
62(11):932–937.
15. Kitaguchi Y, Fujimoto K, Kubo K, Honda T: Characteristics of COPD
phenotypes classified according to the findings of HRCT. Respir Med 2006,
100(10):1742–1752.
16. Hersh CP, Hansel NN, Barnes KC, Lomas DA, Pillai SG, Coxson HO,
Mathias RA, Rafaels NM, Wise RA, Connett JE, Klanderman BJ, Jacobson FL, Gill R,
Litonjua AA, Sparrow D, Reilly JJ, Silverman EK, ICGN Investigators: Transforming
growth factor-beta receptor-3 is associated with pulmonary emphysema.
Am J Respir Cell Mol Biol 2009, 41(3):324–331.
17. Hersh CP, Jacobson FL, Gill R, Silverman EK: Computed tomography
phenotypes in severe, early-onset chronic obstructive pulmonary
disease. COPD 2007, 4(4):331–337.
18. Muller NL, Staples CA, Miller RR, Abboud RT: “Density mask”. An objective
method to quantitate emphysema using computed tomography.
Chest 1988, 94(4):782–787.
19. Nakano Y, Wong JC, de Jong PA, Buzatu L, Nagao T, Coxson HO, Elliott WM,
Hogg JC, Pare PD: The prediction of small airway dimensions using
computed tomography. Am J Respir Crit Care Med 2005, 171(2):142–146.
20. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM,
Gareen IF, Gatsonis C, Marcus PM, Sicks JD: Reduced lung-cancer mortality
with low-dose computed tomographic screening. N Engl J Med 2011,
365(5):395–409.
21. Mets OM, Buckens CF, Zanen P, Isgum I, van Ginneken B, Prokop M,
Gietema HA, Lammers JW, Vliegenthart R, Oudkerk M, van Klaveren RJ,
de Koning HJ, Mali WP, de Jong PA: Identification of chronic obstructive
pulmonary disease in lung cancer screening computed tomographic
scans. JAMA 2011, 306(16):1775–1781.
22. Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beaty TH,
Curran-Everett D, Silverman EK, Crapo JD: Genetic epidemiology of
COPD (COPDGene) study design. COPD 2010, 7(1):32–43.
23. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G,
Knobil K, Lomas DA, MacNee W, Silverman EK, Tal-Singer R, ECLIPSE
Investigators: Evaluation of COPD Longitudinally to Identify Predictive
Surrogate End-points (ECLIPSE). Eur Respir J 2008, 31(4):869–873.
24. Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-complete measure
of health status for chronic airflow limitation. The St George’s Respiratory
Questionnaire. Am Rev Respir Dis 1992, 145(6):1321–1327.
25. Estepar RS, Washko GG, Silverman EK, Reilly JJ, Kikinis R, Westin CF:
Accurate airway wall estimation using phase congruency. Med Image
Comput Comput Assist Interv Int Conf Med Image Comput Comput Assist
Interv 2006, 9(Pt 2):125–134.
26. Hersh CP, Washko GR, Jacobson FL, Gill R, Estepar RS, Reilly JJ, Silverman EK:
Interobserver variability in the determination of upper lobe-predominant
emphysema. Chest 2007, 131(2):424–431.
27. Gevenois PA, De Vuyst P, de Maertelaer V, Zanen J, Jacobovitz D, Cosio MG,
Yernault JC: Comparison of computed density and microscopic
morphometry in pulmonary emphysema. Am J Respir Crit Care Med
1996, 154(1):187–192.
28. Zach JA, Newell JD Jr, Schroeder J, Murphy JR, Curran-Everett D, Hoffman EA,
Westgate PM, Han MK, Silverman EK, Crapo JD, Lynch DA, COPDGene
Investigators: Quantitative computed tomography of the lungs and
airways in healthy nonsmoking adults. Invest Radiol 2012, 47(10):596–602.
29. Hardin M, Silverman EK, Barr RG, Hansel NN, Schroeder JD, Make BJ, Crapo JD,
Hersh CP, COPDGene Investigators: The clinical features of the overlap
between COPD and asthma. Respir Res 2011, 12(1):127.
30. Kim DK, Jacobson FL, Washko GR, Casaburi R, Make BJ, Crapo JD,
Silverman EK, Hersh CP: Clinical and radiographic correlates of
hypoxemia and oxygen therapy in the COPDGene study. Respir Med
2011, 105(8):1211–1221.
31. Kim V, Han MK, Vance GB, Make BJ, Newell JD, Hokanson JE, Hersh CP,
Stinson D, Silverman EK, Criner GJ: The chronic bronchitic phenotype of
COPD: an analysis of the COPDGene Study. Chest 2011, 140(3):626–633.
32. Rambod M, Porszasz J, Make BJ, Crapo JD, Casaburi R: Six-minute walk
distance predictors, including CT scan measures, in the COPDGene
cohort. Chest 2012, 141(4):867–875.
33. Han MK, Kazerooni EA, Lynch DA, Liu LX, Murray S, Curtis JL, Criner GJ,
Kim V, Bowler RP, Hanania NA, Anzueto AR, Make BJ, Hokanson JE,
Crapo JD, Silverman EK, Martinez FJ, Washko GR, COPDGene Investigators:Chronic obstructive pulmonary disease exacerbations in the COPDGene
study: associated radiologic phenotypes. Radiology 2011, 261(1):274–282.
34. Foreman MG, Zhang L, Murphy J, Hansel NN, Make B, Hokanson JE,
Washko G, Regan EA, Crapo JD, Silverman EK, DeMeo DL, COPDGene
Investigators: Early-onset chronic obstructive pulmonary disease is
associated with female sex, maternal factors, and African American race in
the COPDGene Study. Am J Respir Crit Care Med 2011, 184(4):414–420.
35. Swift I, Satti A, Kim V, Make BJ, Newell J, Steiner RM, Wilson C, Murphy JR,
Silverman EK, Criner GJ: Demographic, physiologic and radiographic
characteristics of COPD patients taking chronic systemic corticosteroids.
COPD 2012, 9(1):29–35.
36. Black-Shinn JL, Kinney GL, Wise AL, Regan EA, Make B, Krantz MJ, Barr RG,
Murphy JR, Lynch D, Silverman EK, Crapo JD, Hokanson JE, COPDGene
Investigators: Cardiovascular disease is associated with COPD
severity and reduced functional status and quality of life. COPD
2014, 11(5):546–551.
37. Kinney GL, Black-Shinn JL, Wan ES, Make B, Regan E, Lutz S, Soler X,
Silverman EK, Crapo J, Hokanson JE: Pulmonary function reduction in
diabetes with and without chronic obstructive pulmonary disease.
Diabetes Care 2014, 37(2):389–395.
38. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA,
Pinto Plata V, Cabral HJ: The body-mass index, airflow obstruction,
dyspnea, and exercise capacity index in chronic obstructive pulmonary
disease. N Engl J Med 2004, 350(10):1005–1012.
39. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A,
van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC,
MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J:
Interpretative strategies for lung function tests. Eur Respir J 2005,
26(5):948–968.
40. Pistolesi M, Camiciottoli G, Paoletti M, Marmai C, Lavorini F, Meoni E,
Marchesi C, Giuntini C: Identification of a predominant COPD phenotype
in clinical practice. Respir Med 2008, 102(3):367–376.
41. Cho MH, Washko GR, Hoffmann TJ, Criner GJ, Hoffman EA, Martinez FJ,
Laird N, Reilly JJ, Silverman EK: Cluster analysis in severe emphysema
subjects using phenotype and genotype data: an exploratory
investigation. Respir Res 2010, 11:30.
42. Castaldi PJ, Dy J, Ross J, Chang Y, Washko GR, Curran-Everett D, Williams A,
Lynch DA, Make BJ, Crapo JD, Bowler RP, Regan EA, Hokanson JE, Kinney GL,
Han MK, Soler X, Ramsdell JW, Barr RG, Foreman M, van Beek E, Casaburi R,
Criner GJ, Lutz SM, Rennard SI, Santorico S, Sciurba FC, DeMeo DL, Hersh CP,
Silverman EK, Cho MH: Cluster analysis in the COPDGene study identifies
subtypes of smokers with distinct patterns of airway disease and
emphysema. Thorax 2014, 69(5):415–422.
43. Garcia-Aymerich J, Gomez FP, Benet M, Farrero E, Basagana X, Gayete A,
Pare C, Freixa X, Ferrer J, Ferrer A, Roca J, Galdiz JB, Sauleda J, Monso E,
Gea J, Barbera JA, Agusti A, Anto JM, PAC-COPD Study Group: Identification
and prospective validation of clinically relevant chronic obstructive
pulmonary disease (COPD) subtypes. Thorax 2011, 66(5):430–437.
44. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W,
Miller BE, Rennard S, Silverman EK, Tal-Singer R, Wouters E, Yates JC, Vestbo J,
Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints
(ECLIPSE) investigators: Characterisation of COPD heterogeneity in the
ECLIPSE cohort. Respir Res 2010, 11:122.
45. Martinez CH, Han MK: Contribution of the environment and comorbidities
to chronic obstructive pulmonary disease phenotypes. Med Clin North Am
2012, 96(4):713–727.
46. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, Zulueta J,
Cabrera C, Zagaceta J, Hunninghake G, Celli B, BODE Collaborative Group:
Comorbidities and risk of mortality in patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2012, 186(2):155–161.
47. Clini E, Crisafulli E, Radaeli A, Malerba M: COPD and the metabolic syndrome:
an intriguing association. Intern Emerg Med 2013, 8(4):283–289.
48. Suissa S, Kezouh A, Ernst P: Inhaled corticosteroids and the risks of
diabetes onset and progression. Am J Med 2010, 123(11):1001–1006.
49. O'Byrne PM, Rennard S, Gerstein H, Radner F, Peterson S, Lindberg B,
Carlsson LG, Sin DD: Risk of new onset diabetes mellitus in patients
with asthma or COPD taking inhaled corticosteroids. Respir Med
2012, 106(11):1487–1493.
50. Bon JM, Leader JK, Weissfeld JL, Coxson HO, Zheng B, Branch RA,
Kondragunta V, Lee JS, Zhang Y, Choi AM, Lokshin AE, Kaminski N, Gur D,
Sciurba FC: The influence of radiographic phenotype and smoking status
Hersh et al. BMC Pulmonary Medicine 2014, 14:164 Page 11 of 11
http://www.biomedcentral.com/1471-2466/14/164on peripheral blood biomarker patterns in chronic obstructive
pulmonary disease. PLoS One 2009, 4(8):e6865.
51. U.S. Preventive Services Task Force: Screening for high blood pressure:
U.S. Preventive Services Task Force reaffirmation recommendation
statement. Ann Intern Med 2007, 147(11):783–786.
52. U.S. Preventive Services Task Force: Screening for type 2 diabetes mellitus
in adults: U.S. Preventive Services Task Force recommendation
statement. Ann Intern Med 2008, 148(11):846–854.
53. American Diabetes Association: Standards of medical care in diabetes–2012.
Diabetes Care 2012, 35(Suppl 1):S11–S63.
54. Redelmeier DA, Tan SH, Booth GL: The treatment of unrelated
disorders in patients with chronic medical diseases. N Engl J Med
1998, 338(21):1516–1520.
55. Wouters EF, Bredenbroker D, Teichmann P, Brose M, Rabe KF, Fabbri LM,
Goke B: Effect of the phosphodiesterase 4 inhibitor roflumilast on
glucose metabolism in patients with treatment-naive, newly diagnosed
type 2 diabetes mellitus. J Clin Endocrinol Metab 2012, 97(9):E1720–E1725.
56. Midthjell K, Holmen J, Bjorndal A, Lund-Larsen G: Is questionnaire information
valid in the study of a chronic disease such as diabetes? The Nord-Trondelag
diabetes study. J Epidemiol Community Health 1992, 46(5):537–542.
57. Beckett M, Weinstein M, Goldman N, Yu-Hsuan L: Do health interview
surveys yield reliable data on chronic illness among older respondents?
Am J Epidemiol 2000, 151(3):315–323.
58. Oksanen T, Kivimaki M, Pentti J, Virtanen M, Klaukka T, Vahtera J: Self-report
as an indicator of incident disease. Ann Epidemiol 2010, 20(7):547–554.
59. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA,
Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F,
American Heart Association, National Heart Lung and Blood Institute:
Diagnosis and management of the metabolic syndrome: an American
Heart Association/National Heart, Lung, and Blood Institute Scientific
Statement. Circulation 2005, 112(17):2735–2752.
doi:10.1186/1471-2466-14-164
Cite this article as: Hersh et al.: Non-emphysematous chronic
obstructive pulmonary disease is associated with diabetes mellitus. BMC
Pulmonary Medicine 2014 14:164.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
